Recent developments in limited stage small cell lung cancer

被引：21

作者：

Higgins, Kristin A. ^{[1
]}

Gorgens, Sophia ^{[1
]}

Sudmeier, Lisa J. ^{[1
]}

Faivre-Finn, Corinne ^{[2
]}

机构：

[1] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA

[2] Univ Manchester, Christie NHS Fdn Trust, Dept Thorac Oncol, Manchester, Lancs, England

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2019年 / 8卷

关键词：

Limited stage; small cell lung cancer (SCLC); immunotherapy; prophylactic cranial irradiation (PCI); PROPHYLACTIC CRANIAL IRRADIATION; UNITED-STATES; 7TH EDITION; OPEN-LABEL; CLASSIFICATION; MULTICENTER; PROPOSALS; RADIATION; PROJECT; PHASE-3;

D O I：

10.21037/tlcr.2019.05.13

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Limited stage small cell lung cancer (LS-SCLC) remains a challenging disease, with 5-year overall survival ranging from 30-35% with current standard of care treatment consisting of thoracic radiation to 45 Gy in 30 fractions delivered twice daily, with concurrent platinum/etoposide chemotherapy, followed by prophylactic cranial irradiation (PCI). The randomized, phase III CONVERT study confirmed 45 Gy delivered twice daily to be the optimal radiation fractionation regimen, without significantly increased toxicity when compared to daily radiation to 66 Gy. Immunotherapy is now being studied in addition to chemoradiation, in both the concurrent and consolidative setting. These randomized trials are ongoing. Additionally, the role of PCI compared to MRI surveillance is being evaluated in patients with LS-SCLC in both the North America and Europe. Ideally these ongoing studies will continue to improve outcomes for LS-SCLC.

引用

页码：S147 / S152

页数：6

共 27 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].

Antonia, Scott ;

Goldberg, Sarah B. ;

Balmanoukian, Ani ;

Chaft, Jamie E. ;

Sanborn, Rachel E. ;

Gupta, Ashok ;

Narwal, Rajesh ;

Steele, Keith ;

Gu, Yu ;

Karakunnel, Joyson J. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2016, 17 (03) :299-308

[3] Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].

Aupérin, A ;

Arriagada, R ;

Pignon, JP ;

Le Péchoux, C ;

Gregor, A ;

Stephens, RJ ;

Kristjansen, PEG ;

Johnson, BE ;

Ueoka, H ;

Wagner, H ;

Aisner, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484

[4] Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects [J].

Blanquicett, C ;

Saif, MW ;

Buchsbaum, D ;

Eloubeidi, M ;

Vickers, SM ;

Chhieng, DC ;

Carpenter, MD ;

Sellers, JC ;

Russo, S ;

Diasio, RB ;

Johnson, MR .

CLINICAL CANCER RESEARCH, 2005, 11 (24) :8773-8781

[5] Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial [J].

Christodoulou, Marianna ;

Blackhall, Fiona ;

Mistry, Hitesh ;

Leylek, Ahmet ;

Knegjens, Joost ;

Remouchamps, Vincent ;

Martel-Lafay, Isabelle ;

Farre, Nuria ;

Zwitter, Matjaz ;

Lerouge, Delphine ;

Pourel, Nicolas ;

Janicot, Henri ;

Scherpereel, Arnaud ;

Tissing-Tan, Caroline ;

Peignaux, Karin ;

Geets, Xavier ;

Konopa, Krzysztof ;

Faivre-Finn, Corinne .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) :63-71

[6] Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression [J].

Deng, Liufu ;

Liang, Hua ;

Burnette, Byron ;

Weichselbaum, Ralph R. ;

Fu, Yang-Xin .

ONCOIMMUNOLOGY, 2014, 3 (04)

[7] Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade [J].

Dovedi, Simon J. ;

Cheadle, Eleanor J. ;

Popple, Amy L. ;

Poon, Edmund ;

Morrow, Michelle ;

Stewart, Ross ;

Yusko, Erik C. ;

Sanders, Catherine M. ;

Vignali, Marissa ;

Emerson, Ryan O. ;

Robins, Harlan S. ;

Wilkinson, Robert W. ;

Honeychurch, Jamie ;

Illidge, Timothy M. .

CLINICAL CANCER RESEARCH, 2017, 23 (18) :5514-5526

[8] Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [J].

Faivre-Finn, Corinne ;

Snee, Michael ;

Ashcroft, Linda ;

Appel, Wiebke ;

Barlesi, Fabrice ;

Bhatnagar, Adityanarayan ;

Bezjak, Andrea ;

Cardenal, Felipe ;

Fournel, Pierre ;

Harden, Susan ;

Le Pechoux, Cecile ;

McMenemin, Rhona ;

Mohammed, Nazia ;

O'Brien, Mary ;

Pantarotto, Jason ;

Surmont, Veerle ;

Van Meerbeeck, Jan P. ;

Woll, Penella J. ;

Lorigan, Paul ;

Blackhall, Fiona .

LANCET ONCOLOGY, 2017, 18 (08) :1116-1125

[9] Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer: Survey of US Radiation Oncologists on Current Practice Patterns [J].

Farrell, Matthew J. ;

Yahya, Jehan B. ;

Degnin, Catherine ;

Chen, Yiyi ;

Holland, John M. ;

Henderson, Mark A. ;

Jaboin, Jerry J. ;

Harkenrider, Matthew M. ;

Thomas, Charles R., Jr. ;

Mitin, Timur .

CLINICAL LUNG CANCER, 2018, 19 (04) :371-376

[10]

Gjyshi O, 2019, MULT THOR CANC S MAR

← 1 2 3 →